Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival

Authors :: Tobias Walbert
Louis B. Nabors
J. Bullington
Michael Schulder
Fabio M. Iwamoto
Michael A. Badruddoja
Erin Dunbar
David M. Peereboom
David Tran
Lynn S. Ashby
Frank S. Lieberman
Karen Fink
Trishna Goswami
David Schiff
Ross Lindsay
Surasak Phuphanich
Priya Kumthekar
Jonathan H. Sherman
Nicholas Butowski
David A. Reardon
Source :: Journal of Clinical Oncology. 36:2058-2058
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 2058Background: SL-701 is a novel immunotherapy comprised of synthetic peptides designed to elicit an anti-tumor immune response against GBM targets: interleukin-13 receptor alpha-2, EphrinA2 and S...

Subjects :: Cancer Research
business.industry
medicine.medical_treatment
Immunotherapy
medicine.disease
03 medical and health sciences
0302 clinical medicine
Immune system
Oncology
030220 oncology & carcinogenesis
Relapsed refractory
medicine
Cancer research
Receptor
business
030217 neurology & neurosurgery
Glioblastoma

Tools